AstraZeneca, a pharmaceutical giant, has announced the launch of Evinova, a new health-tech business focused on sharing its expertise in clinical trial design and study delivery. This separate business aims to provide solutions to trial sponsors, clinical research organizations, care teams, and patients at a larger scale.
The company expects this initiative to reduce the time and cost of developing new medicines, bring care closer to patients’ homes, and decrease the burden on health systems. In order to reach a wider audience, AstraZeneca has formed major collaborations with Parexel and Fortrea. These partnerships will allow Evinova’s digital health solutions to be made available to a broad customer base.
Pascal Soriot, AstraZeneca’s Chief Executive, expressed confidence in Evinova’s ability to combine scientific expertise with AI-enabled digital technologies at scale. He believes that this offers a real opportunity for positive change in the healthcare industry.
For more information about Evinova and its partnerships with Parexel and Fortrea, contact Michael Susin at [michael.susin@wsj.com](mailto:michael.susin@wsj.com).